Official Title
Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Brief Summary

It is clear now that SARS-CoV-2 could use angiotensin-converting enzyme 2 (ACE2), the same receptor as SARS-CoV Transmembrane protease serine type 2 (TMPRSS2), a protease belonging to the type II transmembrane serine protease family, cleaves the coronavirus spike protein Serine proteases are inhibited by a diverse group of inhibitors, The best-studied serpins are antithrombin and alpha 1-antitrypsin

Unknown status
Coronavirus

Drug: alpha one antitrypsin inhalation

- we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) as nebulizer every 12 hours for 5 days

Eligibility Criteria

Inclusion Criteria:

1. Positive RT-PCR) assay for SARS-CoV-2

2. Age >18 years

3. Hospitalized

4. Able to give informed consent

Exclusion Criteria:

1. Known allergy to AAT

2. imminent death within next 24 hours

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Saudi Arabia
Locations

Ministry of Health
Mecca, Saudi Arabia

Investigator: mtair
Contact: 0555509022
research-makkah@moh.gov.sa

Contacts

mohammed m othman
00966557881721
Ossman231@yahoo.com

mohammed m othman, Principal Investigator
MOH

Ministry of Health, Saudi Arabia
NCT Number
MeSH Terms
Coronavirus Infections
Severe Acute Respiratory Syndrome
Alpha 1-Antitrypsin
Protein C Inhibitor